Brandon McMahon, MD
Associate Professor, Medicine-Hematology
Medical School
- MD, State University of New York Upstate Medical University (2001)
Undergraduate School
- BA/BS, Boston College (MA) (1997)
Internship
- University of Rochester Program (2004)
Residency
- University of Rochester Program, Chief Resident, Internal Medicine (2005)
Fellowships
- University of Rochester Program, Hematology (2007)
Department
Medicine-HematologyResearch Interests
Dr. McMahon’s research focus has been on mechanisms of abnormal bleeding and clotting in specific disease states, particularly cancers/myeloproliferative neoplasms. This includes evaluating clinical risk factors for developing thrombotic or bleeding complications in specific disease states. He is also interested in clinical trials investigating novel therapeutic options in MPN. Dr. McMahon’s past work has also evaluated use of diagnostic testing or therapeutic interventions in hematology that lack clinical validation, yet are commonly used in everyday practice.Publications
- Kwaan, HC and McMahon, B. Abnormalities in the fibrinolysis pathway and clinical implications. In: Abutalib SA et al ed. Nonmalignant Hematology. Springer International Publishing, Switzerland; 2016.
- Kamath, SD; Cull, EH; Lewandowski, RJ; Stein, BL; and McMahon, BJ. Temporary and permanent inferior vena cava filters in the oncology population. Blood 2016; 128(22): 1423.
- McMahon, B and Kamath, S. Pancytopenia in a patient with hypothyroidism. JAMA 2016; 315(15): 1648.
- Buck, R; Wachsberg, KN; Weaver, AC; Hansen, LO; McMahon, B; Dombrowski, L; and O'Leary, K. Survey of provider transfusion practices for oncology patients in an academic medical center. Southern Medical Journal 2016; 109(4): 267.
- Waisbren, J; Dinnner, S; Altman, J; Frankfurt, O; Helenowski, I; Gao, J; McMahon, B; and Stein, BL. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol2017; 105(1): 44-51.
- Resurrecting response to ruxolitinib: a phase I study testing the combination of Ruxolitinib and the PI3K delta inhibitor umbralisib in ruxolitinib-experienced Myelofibrosis 23rd Congress of European Hematology Association
- TNF-a driven inflammation and mitochondrial dysfunction characterize the platelet hyperreactivity of aging and myeloproliferative neoplasms. 2018; 60th American Society of Hematology Meeting and Exposition
- Davizon-Castillo P; McMahon B; Aguila S; Jones KL; Trahan GD; Ashworth KJ; Bark D; Campbell RA; Higa K; Shih LC; Sanders N; DeGregori J; Rondina MD; DiPaola J. TNFa driven inflammation and mitochondrial dysfunction characterize the platelet hyper-reactivity of aging and myeloproliferative neoplasms. Blood 2018; 132: 1134.
- Streiff MB; Holmstrom B; Angelini D; Ashrani A; Bockenstedt PL; Chesney C; Fanikos J; Fenninger RB; Fogerty AE; Gao S; Goldhaber SZ; Gundabolu K; Hendrie P; Lee AI; Lee JT; Mann J; McMahon B; Millenson MM; Morton C; Ortel T; Ozair S; Paschal R; Shattil S; Siddiqi T; Smock KJ; Soff G; Wang TF; Williams E; Zakarija A; Hammond L; Dwyer MA; Engh AM. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw 2018; 16(11): 1289.
- Kamath, S and McMahon, B. Update in anticoagulation: what IR needs to know. Seminars in Interventional Radiology 2016; 33(2): 122.
- Wilberger, A; McMahon, B; and Ewalt, M. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. Leukemia & Lymphoma 2018; Oct 2: 1-3 (epub ahead of print)
- Kaplan, JB; Stein, BL; McMahon, B; Giles, FJ; and Platanias, L. Evolving therapeutic strategies for the classic Philadelphia negative myeloproliferative neoplasms. EBio Medicine 2016; 3: 17.
- Gotlib J, Gerds AT, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Dehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podoltsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Thota S, Walsh K, Bergman MA, and Sundar H. Systemic Mastocytosis version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018; 16(12): 1500-1537.
- Building blocks of hope: strategies for patients and caregivers living with myeloproliferative neoplasms (MPN). By Sandra Kurtin
- Davizon-Castillo P, McMahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, Montenont E, Nemkov T, D'Alessandro A, Clendenen N, Shih L, Sanders NA, Higa K, Cox A, Padilla-Romo Z, Hernandez G, Wartchow E, Trahan GD, Nozik-Grayck E, Jones K, Pietras EM, DeGregori J, Rondina MT, Di Paola J. TNF-a-driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. Blood. 2019 Aug 29;134(9):727-740. PubMed PMID: 31311815
- Shaikh SS, Kamath SD, Ghosh D, Lewandowski RJ, McMahon BJ. Safety and Outcomes of Permanent and Retrievable Inferior Vena Cava Filters in the Oncology Population. Int J Vasc Med. 2020;2020:6582742. PubMed PMID: 32089887
- Wilberger AC, McMahon B, Ewalt MD. The power of the partner: defying expectations in a case of a myeloproliferative neoplasm with FGFR1 rearrangement. Leuk Lymphoma. 2019 Apr;60(4):1095-1097. PubMed PMID: 30277124
- Kolb JM, Conzen K, Wachs M, Crossno J Jr, McMahon B, Abidi MZ, Pomfret EA, Kriss M. Liver Transplantation for Decompensated Cirrhosis Secondary to Telomerase Reverse Transcriptase Mutation. Hepatology. 2020 Jul;72(1):356-358. PubMed PMID: 31943309
- Gerds AT, Gotlib J, Ali H, Bose P, Dunbar A, Elshoury A, George T, Gundabolu K, Hexner E, Hobbs GS, Jain T, Jamieson C, Kaesberg PR, Kuykendall AT, Madanat Y, McMahon B, Mohan SR, Nadiminti KV, Oh S, Pardanani A, Podoltsev N, Rein L, Salit R, Stein BL, Talpaz M, Vachhani P, Wadleigh M, Wall S, Ward DC, Bergman MA, Hochstetler C. Myeloproliferative Neoplasms version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw . 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.004
- Esparza O, McMahon B, Hernandez G, Le D, Kelher M, Nemkov T, D'Alessandro A, Lopez J, Davizon-Castillo P. Mitochondrial dysfunction in platelets from patients with JAK2 V617F essential thrombocythemia and polycythemia vera underlie thrombo-hemorrhagic complications [abstract]. ISTH Congress 2022.
- Guadalupe Rojas Sanchez, Ph D1*, Orlando Esparza, MD2, Brandon McMahon, MD3, Giovanny Hernandez, BS4*, Dennis Le, BS1*, Travis Nemkov, PhD5*, Angelo D'Alessandro, PhD6, Andrew Thorburn, Ph D7*, José A. López, Pavel Davizon Castillo. Dysregulated Autophagy in Platelets from JAK2V617F-Positive Polycythemia Vera and Essential Thrombocythemia Underlies Bioenergetic Failure As a Possible Mechanism for Thrombohemorrhagic Complications. Abstract 4315, ASH 64th Annual Meeting and Exposition.
- Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis. Clin Cancer Res. 2023 Jul 5;29(13):2375-2384. PubMed PMID: 37036505
- Schreiber AR, Santos J, McMahon B, Buckner TW, Olson C, Alberti MO, Guimarães-Young A, Knoeckel C, Broussard L, Aubrey M, Palmer BE, Weiss E, Connors GR, Brunner S, Wisell JA, Pacheco T, Aisner DL, Gutman JA. A Case of Fetal-Induced Graft-versus-Host Disease. N Engl J Med. 2023 Aug 17;389(7):668-670. PubMed PMID: 37585636
- Halsema K, Mcmahon B. Cancer-Associated Thrombosis: Risk Assessment, Prevention, and Treatment. J Adv Pract Oncol. 2023 Apr;14(3):213-217. PubMed PMID: 37197728
- McCormick C, McMahon B, Galatowitsch J, Castillo A. A 35-year old man with fever. NEJM Evid 2023; 2(5). DOI 10.1056/EVIDmr2300047
- Watts JM; Vannucchi AM; Hunter AM; McMahon B; Tantravahi SK; Iurlo A; Xicoy B; Palandri F; Searle E; Reeves BN; Bose P; Ayala R; Halpern AB; Chen X; Burke LM; Zhou F; Zheng F; Vachhani P. Bromodomain and extra-terminal inhibitor INCB057643 (LIMBER-103) in patients with relapsed or refractory myelofibrosis and other advanced myeloid neoplasms: a phase 1 study. Blood 2023; 142: 750.
- 2. Rojas Sanchez G; Calzada-Martinez J; McMahon B; Esparza O; Hernandez G; Le DL; Wartchow E; Phang T; Nemkov T; D’Alessandro A; Maycotte P; Thorburn A; Lopez JA; Davizon Castillo P. Inflammation mediated by TNFa disrupts the autophagic flux and oxidative phosphorylation of megakaryocytes and platelets through downregulation of STX17. Blood 2023; 142: 2567.
Practice Locations
UCHealth Hematology Clinic - Anschutz Medical Campus1665 Aurora Ct
2nd Floor, Anschutz Cancer Pavilion
Aurora, CO 80045
720-848-0300
UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000
Hospital Affiliation
- University of Colorado Hospital
Center Affiliations
Specialty Information
Specialties- Hematology and Oncology, Board Certification
Personal Interests
Dr. McMahon completed his undergraduate training at Boston College, where he received a Bachelor’s degree in Chemistry with honors. He graduated AOA with his M.D. from SUNY-Upstate Medical University at Syracuse, and then moved to the University of Rochester where he completed his internal medicine residency, followed by a chief residency. He remained that the University of Rochester for his hematology fellowship, which was completed in 2007, and during which he completed the American Society of Hematology Clinical Research Training Institute. He joined the faculty at Northwestern University in Chicago as an Assistant Professor and later Associate Professor of Medicine, where he was heavily involved in clinical operations in hematology, clinical research in thrombotic disorders and MPN, and education, receiving multiple teaching awards and serving as the associate and later director of the Hematology/Oncology fellowship program. He joined the faculty at the University of Colorado in 2016, and will be focusing on thrombosis & MPN in the clinical arena, while remaining active in fellow & resident education. Dr. McMahon’s research involves evaluating mechanisms of thrombotic and bleeding complications in various cancers (particularly MPN), critical evaluation of common medical practices in hematology that lack significant evidence basis, and clinical trials evaluating new therapeutic developments in MPN. He has written many peer-reviewed papers on these topics, several book chapters, and edited a recently published textbook on myeloproliferative neoplasms.
Dr. McMahon completed his undergraduate training at Boston College, where he received a Bachelor’s degree in Chemistry with honors. He graduated AOA with his M.D. from SUNY-Upstate Medical University at Syracuse, and then moved to the University of Rochester where he completed his internal medicine residency, followed by a chief residency. He remained that the University of Rochester for his hematology fellowship, which was completed in 2007, and during which he completed the American Society of Hematology Clinical Research Training Institute. He joined the faculty at Northwestern University in Chicago as an Assistant Professor and later Associate Professor of Medicine, where he was heavily involved in clinical operations in hematology, clinical research in thrombotic disorders and MPN, and education, receiving multiple teaching awards and serving as the associate and later director of the Hematology/Oncology fellowship program. He joined the faculty at the University of Colorado in 2016, and will be focusing on thrombosis & MPN in the clinical arena, while remaining active in fellow & resident education. Dr. McMahon’s research involves evaluating mechanisms of thrombotic and bleeding complications in various cancers (particularly MPN), critical evaluation of common medical practices in hematology that lack significant evidence basis, and clinical trials evaluating new therapeutic developments in MPN. He has written many peer-reviewed papers on these topics, several book chapters, and edited a recently published textbook on myeloproliferative neoplasms.